Equipoise: The Veterinary AAS — Educational Reference
Last updated: March 2026
Boldenone undecylenate (Equipoise) was originally developed as a veterinary injectable for horses. Its 1,2-double bond modification of testosterone produces mild aromatization, strong red blood cell stimulation, and appetite increase. This educational reference covers its pharmacology, effects, cardiovascular risks, and the extremely long detection window.
(vs testosterone = 100:100)
Intramuscular injection
Detection: up to 5 months
📋 On this page
How Boldenone Works
Boldenone is testosterone with an added 1,2-double bond in the A-ring. This seemingly small change profoundly alters its pharmacology — reducing androgenic and estrogenic activity while enhancing its erythropoietic (RBC-stimulating) effects.
Boldenone strongly stimulates erythropoietin (EPO) production in the kidneys, driving red blood cell production. This raises hematocrit, hemoglobin, and oxygen-carrying capacity — producing endurance benefits but also significantly increasing blood viscosity. Hematocrit above 52–54% dramatically increases thrombosis, stroke, and cardiac event risk. Regular hematocrit monitoring is essential harm reduction.
Boldenone is uniquely potent for appetite stimulation among AAS — the mechanism is not fully characterized but likely involves central androgen receptor signaling and ghrelin modulation. This makes it useful for bulking phases where caloric surplus is desired but can complicate cutting protocols. Users report dramatically increased hunger within weeks of initiating use.
The 1,2-double bond slows aromatase conversion to estradiol. Boldenone aromatizes at roughly 50% the rate of testosterone — producing moderate but manageable estrogenic activity. Water retention and gynecomastia risk are lower than testosterone or Dianabol. An aromatase inhibitor may still be needed at higher doses or in estrogen-sensitive individuals.
The undecylenate ester gives boldenone an approximate 14-day half-life in vivo. This extends its active life for weekly or bi-weekly dosing convenience — but means it accumulates slowly (full effect not felt for 4–6 weeks) and detection windows extend to 4–5 months in urine testing. WADA long-term metabolites may be detectable for even longer periods.
What the Research Shows
Data from pharmacological studies, veterinary research, and clinical literature on boldenone undecylenate.
Side Effects & Risks
Key Takeaways
- Strong erythropoiesis stimulation — hematocrit must be monitored
- Mild aromatization (~50% of testosterone) — manageable estrogen side effects
- Notable appetite stimulation — useful for caloric surplus
- ~14-day half-life from undecylenate ester
- Extremely long detection window (4–5+ months)
- HPTA suppression — PCT required, recovery prolonged by long half-life
- No approved human medical use in the US
- Long-term cardiovascular outcomes at bodybuilding doses
- Precise mechanism of appetite stimulation
- Optimal hematocrit monitoring thresholds for harm reduction
- Long-term WADA detection limits for newer metabolite tests
- Individual variation in erythropoietic response
🛒 Essential Monitoring Supplies
Hematocrit monitoring is critical harm reduction for Equipoise use — elevated RBC viscosity is the primary serious risk.
Related Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and harm reduction purposes only. It is not medical advice. Boldenone undecylenate (Equipoise) is a Schedule III controlled substance in the United States with no approved human medical use. It is banned by WADA and all major sports organizations. Use carries significant health risks including thrombosis, cardiovascular disease, and hormonal disruption. Hematocrit elevation from boldenone use can cause serious, life-threatening clotting events. Consult a qualified physician before making any decisions regarding hormone use. HighPeptides does not endorse or encourage the use of controlled substances.